Angela Rose Brannon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angela Rose Brannon has a total of 536 co-authors. Here are the top co-authors by number of shared publications:
- Michael F. Berger
Memorial Sloan Kettering Cancer Center
77 shared publications - Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
62 shared publications - Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
59 shared publications - Debyani Chakravarty
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
56 shared publications - Maria E. Arcila
Memorial Sloan Kettering Cancer Center, New York, NY
50 shared publications - Ritika Kundra
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
47 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Springer Nature in npj Breast Cancer
Tumor and ctDNA concordance of actionable alterations in metastatic breast cancer
- 20 October 2026
- Published by Springer Nature in npj Breast Cancer
Open AccessTumor and ctDNA concordance of actionable alterations in metastatic breast cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 1: Characteristics of the IMPACT cohort. Violin plots of (A) age at sample acquisition and (B) age at patient’s first diagnosis separated by amplification status of MYCf genes. Bar plot showing (C) the stage of the cancer at the patient’s first diagnosis and (D) patient sex separated by MYCf amplification status. (E-G) Scatter plot showing the correlation between fraction of genome altered (FGA) and segment size for amplifications in (E) MYC, (F) MYCN, and (G) MYCL. On each plot is shown Pearson’s R and p-value. (H) Violin plots showing the clonality (cellular fraction divided by sample purity derived from FACETS) of MYCf amplifications.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 1: Characteristics of the IMPACT cohort. Violin plots of (A) age at sample acquisition and (B) age at patient’s first diagnosis separated by amplification status of MYCf genes. Bar plot showing (C) the stage of the cancer at the patient’s first diagnosis and (D) patient sex separated by MYCf amplification status. (E-G) Scatter plot showing the correlation between fraction of genome altered (FGA) and segment size for amplifications in (E) MYC, (F) MYCN, and (G) MYCL. On each plot is shown Pearson’s R and p-value. (H) Violin plots showing the clonality (cellular fraction divided by sample purity derived from FACETS) of MYCf amplifications.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 2: Expression of MYC and MYCL in various cancer types. (A) Boxplot of the expression of MYCL separated by cancer type. Cancer types were included if they contained at least five samples with MYCL amplifications. Each point represents one sample, and samples are separated by amplification status of MYCL. BH-adjusted p-values are shown. (B-C) Boxplots of ssGSEA for samples in (Figure 3A) for two Hallmark pathways: MYC Targets V1 (B) and MYC Targets V2 (C). Nominal p-values are shown when below 0.05. (D-H) Boxplots comparing expression of MYC across cancer types, separated by alteration status of five genes that were identified through cross-validation GLM-NET as correlating with MYC expression: CDKN2A, ARID4A, PIK3CA, TERT, and TP53, respectively. (I) Boxplots comparing expression of MYC in HR positive breast carcinoma, separated by amplification status of MYC and alterations in PIK3CA. For (A-I), expression is shown as natural log of RSEM, the size of each point represents the ploidy-corrected total copy number of MYC, and p-values are derived from Wilcoxon tests.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 2: Expression of MYC and MYCL in various cancer types. (A) Boxplot of the expression of MYCL separated by cancer type. Cancer types were included if they contained at least five samples with MYCL amplifications. Each point represents one sample, and samples are separated by amplification status of MYCL. BH-adjusted p-values are shown. (B-C) Boxplots of ssGSEA for samples in (Figure 3A) for two Hallmark pathways: MYC Targets V1 (B) and MYC Targets V2 (C). Nominal p-values are shown when below 0.05. (D-H) Boxplots comparing expression of MYC across cancer types, separated by alteration status of five genes that were identified through cross-validation GLM-NET as correlating with MYC expression: CDKN2A, ARID4A, PIK3CA, TERT, and TP53, respectively. (I) Boxplots comparing expression of MYC in HR positive breast carcinoma, separated by amplification status of MYC and alterations in PIK3CA. For (A-I), expression is shown as natural log of RSEM, the size of each point represents the ploidy-corrected total copy number of MYC, and p-values are derived from Wilcoxon tests.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 3: Overall survival analysis for six cancer types. Multivariate analysis of overall survival for patients with MYC amplifications. Cancer types are as follows: (A) hormone receptor (HR) positive breast cancer, (B) colorectal cancer, (C) lung adenocarcinoma, (D), ovarian cancer, (E) prostate cancers, (F) and uterine cancer. Covariates include fraction of genome altered (FGA), patient sex, age at sample acquisition, age and stage at first diagnosis, and binary variables for focality of the amplification, the amplitude of the total copy number compared to the median, and alterations in cooccurring genes. Hazard Ratios (HR), 95% confidence intervals (CI) and nominal p-values are shown to the right. BH-adjusted p-values can be found in Supplementary Table 7.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Supplementary Figure 3: Overall survival analysis for six cancer types. Multivariate analysis of overall survival for patients with MYC amplifications. Cancer types are as follows: (A) hormone receptor (HR) positive breast cancer, (B) colorectal cancer, (C) lung adenocarcinoma, (D), ovarian cancer, (E) prostate cancers, (F) and uterine cancer. Covariates include fraction of genome altered (FGA), patient sex, age at sample acquisition, age and stage at first diagnosis, and binary variables for focality of the amplification, the amplitude of the total copy number compared to the median, and alterations in cooccurring genes. Hazard Ratios (HR), 95% confidence intervals (CI) and nominal p-values are shown to the right. BH-adjusted p-values can be found in Supplementary Table 7.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Summarizes considerations relevant to the representativeness and generalizability of patient cohorts in studies of the cancer types evaluated.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Summarizes considerations relevant to the representativeness and generalizability of patient cohorts in studies of the cancer types evaluated.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Number of samples from TCGA cohort used in expression analysis separated by type of MYCf amplification. If cancer type was not used in a comparison, values appear as NA.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Number of samples from TCGA cohort used in expression analysis separated by type of MYCf amplification. If cancer type was not used in a comparison, values appear as NA.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Values derived from the cross-validated GLM-NET modeling expression by ploidy-corrected copy number, cancer type, and genes with alterations co-occurring with MYC amplifications across cancer types in TCGA samples.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Values derived from the cross-validated GLM-NET modeling expression by ploidy-corrected copy number, cancer type, and genes with alterations co-occurring with MYC amplifications across cancer types in TCGA samples.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Values derived from the cross-validated GLM-NET modeling expression by ploidy-corrected copy number, and genes with alterations co-occurring with MYC amplifications in each of six cancer types in TCGA samples.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Values derived from the cross-validated GLM-NET modeling expression by ploidy-corrected copy number, and genes with alterations co-occurring with MYC amplifications in each of six cancer types in TCGA samples.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Comparison of focal and broad MYC amplification frequency across the most common cancer types in Figure 1A. For each cancer type, the ratio was calculated as the number of focal divided by the number of total MYC amplifications. The background, expected ratio was based on all cancer types in Figure 1A, excluding the cancer type in question. Binomial test was used for comparison with nominal and BH-corrected p-values shown.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Comparison of focal and broad MYC amplification frequency across the most common cancer types in Figure 1A. For each cancer type, the ratio was calculated as the number of focal divided by the number of total MYC amplifications. The background, expected ratio was based on all cancer types in Figure 1A, excluding the cancer type in question. Binomial test was used for comparison with nominal and BH-corrected p-values shown.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Co-occurrence and mutual exclusivity of MYCf genes as depicted in Figure 2. Columns include gene or gene focality from Figure 2A and B, respectively, alteration being tested, the number of samples per alteration combination, odds ratio (OR), q-value, and cancer type.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors
Co-occurrence and mutual exclusivity of MYCf genes as depicted in Figure 2. Columns include gene or gene focality from Figure 2A and B, respectively, alteration being tested, the number of samples per alteration combination, odds ratio (OR), q-value, and cancer type.